-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Developed by Takeda Pharmaceutical Co., Ltd. of Japan, lanso laazole for injection was first listed in Europe in December 1991 and approved for listing in Japan in December 1992.
May 2004, the injectable lanso laazole developed by Takeda Pharmaceutical Industries Co., Ltd. of Japan was approved for listing by the U.S. Food and Drug Administration (the product was de-listed in the United States in February 2007).
currently used in the injection of lansolazole original research drugs have not been listed in China.
injections with lansolazole for oral therapy are not applicable to the following diseases: gastric ulcers with bleeding, heterosome ulcers, acute stress ulcers, acute gastric mucosal lesions.
is a proton pump inhibitor.
the drug is distributed in the acidic environment of the mucous membrane wall cells in the stomach and transformed into an active metabolite.
this metabolite is combined with the -based binding of the H-, K-ATP enzyme present at the site of acid production, which inhibits acid secretion by inhibiting the activity of the H-, K-ATP enzyme.
.